Cancer immunotherapy (Q27026870)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cancer immunotherapy	scientific article

Statements

scholarly article

1 reference

Cancer immunotherapy (English)

0 references

1 reference

based on heuristic

inferred from title

author name string

Thomas F. Gajewski

1

1 reference

language of work or name

1 reference

publication date

April 2012

1 reference

Molecular Oncology

1 reference

6

1 reference

2

1 reference

242-50

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Induction of intestinal Th17 cells by segmented filamentous bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

21 March 2017

Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

7 April 2017

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

7 April 2017

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

7 April 2017

Modulation of immune homeostasis by commensal bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Adoptive cell therapy for the treatment of patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Transient T cell depletion causes regression of melanoma metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Immune resistance orchestrated by the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

IDO and tolerance to tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Melanoma vaccines: early progress and future promises

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

B7-H1 pathway and its role in the evasion of tumor immunity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Integrating IL-12 into therapeutic cancer vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

T-cell recognition of self peptides as tumor rejection antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 September 2017

Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

31 May 2018

Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

31 May 2018

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.002

21 January 2018

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.002

21 January 2018

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.002

21 January 2018

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.002

21 January 2018

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.002

21 January 2018

Phase I/II trial of tremelimumab in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.002

21 January 2018

Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites

1 reference

https://api.crossref.org/works/10.1016%2FJ.MOLONC.2012.01.002

21 January 2018

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 November 2018

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3345039

28 November 2018

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

1 reference

https://pubmed.ncbi.nlm.nih.gov/22248437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22248437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Priming of naive T cells inside tumors leads to eradication of established tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22248437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site

1 reference

https://pubmed.ncbi.nlm.nih.gov/22248437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/22248437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22248437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22248437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.MOLONC.2012.01.002

0 references

PMC publication ID

1 reference

PubMed publication ID

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27026870&oldid=1412003579"